Hydroxychloroquine-Induced Retinal Toxicity

Background

Hydroxychloroquine (Plaquenil, Covis Pharmaceuticals, Inc., Zug, Switzerland) is one of a number of systemic medications that may cause retinal toxicity. Patients on long-standing Hydroxychloroquine should have regular medical examinations by an ophthalmologist to screen for maculopathy.

• References

• 1 Marmor MF, Kellner U, Lai TY et al. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy by the American Academy of Ophthalmology Update. Ophthalmology 2011; 118: 415-422
• 2 Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453-1460
• 3 Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2013; 6: 35-43
• 4 Payne J, Hubbard G, Aaberg T et al. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol 2011; 95: 245-250
• 5 Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983; 75: 25-34
• 6 Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991; 23: 292-296
• 7 Tsang AC, Ahmadi Pirshahid S, Virgili G et al. Hydroxychloroquine and chloroquine retinopathy – a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 2015; 122: 1239-1251.e4
• 8 Nika M, Blachley TS, Edwards P et al. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol 2014; 132: 1199-1208